Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Septosyl is a topical ophthalmic antibiotic ointment containing sulfadimidine (also known as sulfamethazine). Developed and marketed by the Hungarian company PannonPharma, it belongs to the sulfonamide class of antibiotics. The drug exerts its bacteriostatic effect by competitively inhibiting the enzyme dihydropteroate synthase (DHPS), which is a critical step in the bacterial synthesis of folic acid. By blocking the production of dihydrofolic acid, it prevents bacterial nucleic acid synthesis and growth. Septosyl is primarily indicated for the treatment of superficial bacterial infections of the eye, including conjunctivitis, blepharitis, and keratitis, and is also used for the prevention of neonatal ophthalmia caused by susceptible organisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfadimidine.